How AIRE Protein Protects Against Type 1 Diabetes—and What Happens When It Fails

The thymus is a small organ behind the breastbone that serves as a training ground for immune cells. Before T cells enter the bloodstream, they must pass a critical test: can they recognize and respond to invaders without attacking the body's own tissues? This process is called central immune tolerance.

A protein called AIRE acts as an instructor in this training process. It helps thymic cells present disease-associated proteins—including those found in the pancreas—to developing T cells. When the immune system learns to tolerate these self-antigens, it learns not to attack them.

Researchers used two experimental approaches to study AIRE deficiency. First, they reduced AIRE in laboratory stem cells and tracked how thymic epithelial cells—the cells that make up the thymus structure—developed. Second, they reduced AIRE specifically in the thymus of NOD/Ltj mice, a strain that naturally develops type 1 diabetes.

Without functional AIRE, the thymus failed to properly generate and organize the cells that normally present self-antigens. These structural changes were accompanied by shifts in molecular markers. Specifically, the loss of AIRE downregulated a molecule called SPP1 while increasing molecules called Fn1 and CD44—changes that disrupt the tissue environment needed for proper immune training.

In mice with thymic AIRE deficiency, the protective training system collapsed. Blood glucose levels rose faster, and the pancreas showed more severe immune infiltration (insulitis). The thymus also expressed fewer proteins associated with pancreatic beta cells and other type 1 diabetes targets, suggesting the immune cells were not learning to tolerate these critical tissues.

At the same time, the mice developed more autoreactive T cells—cells that attack the body's own tissues. They showed higher CD4+ T cell counts and fewer regulatory T cells (Tregs), which normally suppress autoimmune responses. When researchers tested the immune cells directly, they found increased activation and proliferation against type 1 diabetes antigens.

A strength of this research is that the molecular changes observed in laboratory stem cell experiments matched what occurred in living mice. The same shifts in SPP1, Fn1, and CD44 appeared in both settings, suggesting these molecules are genuine markers of AIRE deficiency and immune dysfunction.

When researchers used a rescue approach to restore AIRE function in cells, some—but not all—of the molecular disruptions improved. This partial recovery suggests AIRE is necessary but perhaps not sufficient on its own for full immune tolerance, pointing to other factors that may also play a role.

These findings strengthen our understanding of how central immune tolerance breaks down in type 1 diabetes. AIRE deficiency doesn't cause type 1 diabetes on its own in humans—most people inherit functional AIRE genes. However, studying what goes wrong without AIRE reveals the cellular and molecular mechanisms that normally prevent autoimmunity.

This knowledge may inform future research into whether supporting or enhancing thymic function could help protect immune tolerance in people at risk for type 1 diabetes. Any therapeutic approach would need to be rigorously tested before use in patients.

Source: International journal of molecular sciences. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.